Whitepaper by Isla Health
NHS Trusts are currently at a critical turning point in urology care. In direct alignment with the DHSC and NHS England’s January 2025 plan for reforming elective care, there is a clear national mandate to reduce unnecessary follow-up appointments. With the urology waiting list standing at 411,000 active pathways, the move from “analogue to digital” is no longer a future goal; it is a present necessity.
By automating PSA surveillance, Trusts can successfully implement the GIRFT Urology report (April 2024) recommendations to optimise pathways, avoid unnecessary attendances, and ensure remote monitoring is used for patients with stable cancer.
This would allow Clinical Nurse Specialists to shift from manual data retrieval, which currently consumes circa 80% of their time, to high-value clinical decision-making.
By adopting digital-first PSA pathways, Trusts have the potential to achieve:
- c. 87% faster processing: Reducing time per patient from 15 minutes to just 2 minutes.
- c. 60-80% admin reduction: Eliminating the manual burden of data entry and letter writing.
- Enhanced clinical safety: Replacing high-risk manual spreadsheets with an automated digital safety net that ensures no “Red Flag” is missed.
In our PSA whitepaper, we show you how to optimise pathways and implement remote PSA monitoring to effectively avoid unnecessary attendances for patients with stable cancer.
